Cochrane · systematic review · CD009594
The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission
Muchtar, E, Vidal, L, Ram, R, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
11
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 27.3%Moderate 5 · 45.5%High 3 · 27.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: patients with APL in first complete remission
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival [range of median | no estimate extracted | 892 participants | Low |
Disease‐free survival [range of median | no estimate extracted | 1209 participants | High |
Adverse events requiring discontinuation [range of median | no estimate extracted | 906 participants | Moderate |
Relapse rate [range of median | no estimate extracted | 896 participants | Moderate |
Comparison
Population: patients with APL in first complete remission
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival [range of median | no estimate extracted | 632 participants | Moderate |
Disease‐free survival [range of median | no estimate extracted | 670 participants | High |
Relapse rate [range of median | no estimate extracted | 425 participants | Moderate |
Comparison
Population: patients with APL in first complete remission
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival [range of median | no estimate extracted | 1033 participants | Moderate |
Disease‐free survival [range of median | no estimate extracted | 1028 participants | High |
Subgroup analysis in pediatric patients: Overall survival [range of median | no estimate extracted | 133 participants | Low |
Subgroup analysis in pediatric patients: Disease‐free survival [range of median | no estimate extracted | 127 participants | Low |